Skip to content
BiologicalX

Comparison

Clomiphene vs GHRP-2

Side-by-side of Clomiphene and GHRP-2. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Clomiphene

  • SERM that blocks estrogen-receptor negative feedback at the hypothalamus, raising LH and FSH
  • FDA approved 1967 for ovulation induction in anovulatory women at 50 to 100 mg cycle days 5 to 9
  • Off-label in men at 12.5 to 25 mg daily raises endogenous testosterone while preserving fertility
  • Enclomiphene (trans-isomer) is preferred for male use; cleaner PK and less estrogenic side effect burden
  • Visual disturbances occur in ~1 to 2% of users; persistent symptoms warrant immediate cessation
  • Letrozole has displaced clomiphene as first-line ovulation induction in PCOS (Legro 2014)

GHRP-2

  • Hexapeptide ghrelin-receptor agonist that stimulates pulsatile GH release within 15 to 30 minutes
  • Strongest appetite signal among GHRPs at standard doses; centrally mediated via NPY/AgRP
  • Produces measurable cortisol and prolactin rise (more than ipamorelin, less than GHRP-6)
  • Approved in Japan as pralmorelin for GH-deficiency diagnostic provocation; not FDA approved
  • Anecdotal protocols use 100 to 300 mcg subcutaneously 2 to 3 times daily on an empty stomach
  • Banned by WADA under S2; detection methods validated in accredited labs

Side-by-side

Attribute Clomiphene GHRP-2
Category pharmaceutical peptide
Also known as Clomid, clomiphene citrate, Serophene, enclomiphene Growth Hormone Releasing Peptide 2, Pralmorelin, KP-102, GPA-748
Half-life (hr) 168 0.5
Typical dose (mg) 25 0.1
Dosing frequency 5-day pulse cycle days 5 to 9 (women); daily or every other day (men, off-label) 2-3x daily
Routes oral subcutaneous, intranasal, intravenous
Onset (hr) 6 0.25
Peak (hr) 7 0.5
Molecular weight 405.96 817.97
Molecular formula C26H28ClNO C45H55N9O6
Mechanism Selective estrogen receptor modulator that antagonizes estrogen at the hypothalamus and pituitary, increasing GnRH and gonadotropin output, which drives gonadal steroidogenesis. Hexapeptide agonist of the growth-hormone secretagogue receptor (GHS-R1a). Suppresses hypothalamic somatostatin tone and stimulates pituitary somatotrophs, producing a pulsatile GH release with secondary cortisol, prolactin, and ACTH elevation.
Legal status Prescription only (FDA approved for ovulation induction; off-label in men) Not FDA approved; approved in Japan as pralmorelin (diagnostic); research-use-only grey market in US/EU; banned by WADA
WADA status banned banned
DEA / Rx Rx only (not a controlled substance) Not scheduled in US (research chemical); approved diagnostic in Japan
Pregnancy Category X; contraindicated in pregnancy Insufficient data; not recommended
CAS 911-45-5 158861-67-7
PubChem CID 1548953 9919072
Wikidata Q416785 Q7235681

Safety profile

Clomiphene

Common side effects

  • hot flushes
  • mood changes
  • abdominal discomfort
  • breast tenderness
  • visual disturbances (rare)
  • headache

Contraindications

  • pregnancy
  • active liver disease
  • ovarian cysts (not PCOS-related)
  • uncontrolled thyroid or adrenal disorder
  • abnormal uterine bleeding of undetermined origin
  • hormone-sensitive cancer

Interactions

  • tamoxifen: competing SERM activity; not used together(moderate)
  • ospemifene: competing SERM activity(moderate)
  • anastrozole: additive estrogen reduction; sometimes combined in male protocols(minor)
  • TRT (exogenous testosterone): TRT suppresses HPT axis that clomiphene targets; do not combine(moderate)

GHRP-2

Common side effects

  • acute hunger
  • head pressure or flushing
  • water retention
  • vivid dreams
  • tingling at injection site
  • transient lethargy

Contraindications

  • pregnancy
  • active malignancy
  • history of pituitary tumor
  • uncontrolled diabetes
  • severe insulin resistance

Interactions

  • CJC-1295: synergistic GH release; commonly co-administered for larger pulse(minor)
  • sermorelin: additive GH release via parallel GHRH and ghrelin pathways(minor)
  • insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
  • corticosteroids: blunt GH response and amplify cortisol load(moderate)

Which Should You Take?

Clomiphene comes out ahead for most readers on the criteria we weight: 2 catalogued goals, prescription-only, oral dosing, with a Tier-A outcome catalogued. GHRP-2 is the right call when one of the conditionals below applies.

  • If your priority is hormonal optimization, pick Clomiphene.
  • If your priority is fertility, pick Clomiphene.
  • If your priority is growth-hormone axis, pick GHRP-2.
  • If your priority is post-training recovery, pick GHRP-2.

Edge case: If you cannot self-administer injections, Clomiphene is the only oral option in this pair.

Default choice: Clomiphene. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for GHRP-2 only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Clomiphene and GHRP-2?

Clomiphene and GHRP-2 differ in category (pharmaceutical vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Clomiphene or GHRP-2?

Clomiphene half-life is 168 hours; GHRP-2 half-life is 0.5 hours.

Can you stack Clomiphene with GHRP-2?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper